Citrate is a key energy sensor that plays a central role in carbohydrate metabolism, energy production, and histone acetylation. The intracellular level of citrate is tightly controlled through a balance of biosynthesis and transport. In the liver, the solute carrier family 13 member 5 (SLC13A5), a sodium-coupled citrate transporter, is essential for the import of citrate from the circulation to hepatocytes, a process that can be perturbed by both xenobiotic and endobiotic stimuli. Recent studies have shown that expression of SLC13A5 was increased in obese, non-alcoholic fatty liver disease (NAFLD) patients, high-fat diet (HFD)-treated rhesus monkeys, and in xenobiotic-treated human and rat hepatocytes, suggesting upregulation of SLC13A5 can be a risk factor for metabolic disorders. In contrast, deletion of SLC13A5 protects mice from HFD-induced hepatic steatosis and mutations of the SLC13A5 ortholog in D. melanogaster promote longevity. However, despite the emerging importance of SLC13A5 in energy homeostasis, the mechanism(s) by which the SLC13A5 gene is transcriptionally regulated and whether clinically used drugs disturb the expression of this transporter are not well characterized. Moreover, whether SLC13A5 affects hepatic functions beyond lipid homeostasis is largely unknown. The overall objective of this proposal is to understand the molecular mechanisms governing hepatic SLC13A5 gene expression and to delineate the role of SLC13A5 in human liver cell proliferation. To this end, we have shown that 1) prototypical activators of the constitutive androstane receptor (CAR) and the pregnane X receptor (PXR) robustly induce expression of human SLC13A5; 2) knockdown of SLC13A5 attenuates the proliferation of hepatocellular carcinoma cells; and 3) expression of SLC13A5 is inversely correlated with the activation of AMPK signaling. Building on these preliminary results, we hypothesize that CAR and PXR are key regulators of the inductive expression of SLC13A5 in the liver, and SLC13A5 functions as a nutrient regulator altering the proliferation of hepatoma cells by modulating AMPK/mTOR signaling pathways. This central hypothesis will be tested in the following specific aims:
Aim 1. Define the role of CAR and PXR in xenobiotic- induced expression of SLC13A5;
Aim 2. Elucidate the mechanism(s) underlying CAR- and PXR-mediated induction of SLC13A5;
Aim 3. Determine the effects of SLC13A5 on hepatoma cell proliferation. The outcomes are expected to provide fundamental novel knowledge on the transcriptional regulation of SLC13A5 in the liver, and to delineate a crucial role of SLC13A5 in bridging energy metabolism with liver cancer progression.

Public Health Relevance

The proposed studies will yield fundamental and novel knowledge regarding the regulation of SLC13A5 expression through specific interactions with CAR and PXR, which will considerably improve our understanding of xenobiotic-mediated alteration of energy homeostasis in the liver. The anticipated outcome will offer proof- of-concept evidence that targeted disruption of SLC13A5 affects the proliferation of human hepatoma cells. This research may eventually lead to novel strategies in controlling metabolic disorders and liver cancer.

National Institute of Health (NIH)
National Institute of General Medical Sciences (NIGMS)
Research Project (R01)
Project #
Application #
Study Section
Xenobiotic and Nutrient Disposition and Action Study Section (XNDA)
Program Officer
Garcia, Martha
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Maryland Baltimore
Schools of Pharmacy
United States
Zip Code
Wolfson, Benjamin; Lo, Pang-Kuo; Yao, Yuan et al. (2018) Impact of miR-140 Deficiency on Non-Alcoholic Fatty Liver Disease. Mol Nutr Food Res 62:e1800189
Lynch, Caitlin; Mackowiak, Bryan; Huang, Ruili et al. (2018) Identification of Modulators that Activate the Constitutive Androstane Receptor from the Tox21 10K Compound Library. Toxicol Sci :
Yang, Xiaosong; Pan, You; Qiu, Zhaojun et al. (2018) RNF126 as a Biomarker of a Poor Prognosis in Invasive Breast Cancer and CHEK1 Inhibitor Efficacy in Breast Cancer Cells. Clin Cancer Res 24:1629-1643
Hedrich, William D; Fandy, Tamer E; Ashour, Hossam M et al. (2018) Antibody-Drug Conjugates: Pharmacokinetic/Pharmacodynamic Modeling, Preclinical Characterization, Clinical Studies, and Lessons Learned. Clin Pharmacokinet 57:687-703
Mackowiak, Bryan; Hodge, Jessica; Stern, Sydney et al. (2018) The Roles of Xenobiotic Receptors: Beyond Chemical Disposition. Drug Metab Dispos 46:1361-1371